Novartis Confident About Further Growth For 'Big Two'
New Indications On Track For Cosentyx And Entresto
As well as highlighting Novartis's burgeoning pipeline, the Swiss major's CEO is confident that its biggest earners will continue to growth for the next five years at least.
You may also be interested in...
Novartis Holds Out For Happier Second Half Of 2021
The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.
Merck & Co. Pushes Back On Modest Projections For Verquvo
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
Novartis MS Drug Kesimpta Quick Out Of The Blocks
Kesimpta is a treatment option for multiple sclerosis patients "that doesn't need compromise, the trade-off between high efficacy and high treatment burden," Novartis neuroscience chief Norman Putzki tells Scrip.